This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
1,2 People living with AFib face an increased risk of stroke, heart failure and death, and many rely on cardiac ablation to treat the condition effectively. The trial showed the Volt PFA System achieved pulmonary vein isolation (PVI) the method of destroying tissue causing a patient's AFib in 99.1% Procedural flexibility.
In particular, the study showed superiority in the percentage of patients that achieved freedom from atrial fibrillation (AF) with or without anti-arrhythmic drugs at 12 months after a tailored cardiac ablation guided by AI in combination with PVI when compared to PVI alone. tim.hodson Fri, 02/14/2025 - 09:57 Feb.
Ablation index (AI)-guided pulmonary vein isolation (PVI) has enhanced procedural outcomes for atrial fibrillation (AF).1 1 However, patients with persistent AF present higher recurrence rates due to advanced atrial remodeling,2-3 represented by the left atrial low voltage area (LVA), compared to those with paroxysmal AF.
Superior vena cava (SVC) conduction delay or isolation during right superior pulmonary vein (RSPV) ablation using thermal ablationtechnologies has been previously described.1,2 1,2 No reports regarding the impact of pulsed-field ablation (PFA) on the SVC exist.
Food and Drug Administration (FDA), has granted approval to Boston Scientific for its FARAPULSE Pulsed Field Ablation System. A company statement reported that its PFA System is indicated for the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, paroxysmal (i.e.,
This is the first PFA technology to receive FDA approval and follows the recent European CE (Conformité Européenne) Mark of the PulseSelect PFA system in November. In my clinical experience with the catheter, it was designed for AF ablation procedures.
During its Annual Conference, HRS 2024, the Heart Rhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrial fibrillation (AF). See full findings from the FARADISE, admIRE Study, and Advent Trial here.
BackgroundCatheter ablation is frequently used to manage recurrent atrial fibrillation (AF) resistant to drug therapy, with pulmonary vein isolation (PVI) as a key tactic. The reconnection of pulmonary veins was discovered primarily in the anterior region of the right superior PV and the superior portion of the left superior PV.
Outcomes of ablation with the FARAPULSE PFA System – a nonthermal treatment in which electric fields selectively ablate heart tissue – will be compared to outcomes following use of anti-arrhythmic drug (AAD) therapy, which is commonly prescribed for patients living with persistent AF. The company now anticipates U.S. Circulation.
Titled "Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy Atrial Fibrillation Ablation," the study was presented as a late-breaker at the 29th Annual International AF Symposium. Biosense Webster's zero fluoroscopy workflow is the first and only such workflow available in a radiofrequency (RF) cardiac ablation device.
Objective Pulsed-field ablation (PFA) is a new technology of catheter ablation for atrial fibrillation (AF). This research is to investigate the feasibility of a new strategy (transoesophageal echocardiography-guided pulsed field ablation, TEEP) to guide PFA for AF with no contrast and zero fluoroscopy.
Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart Treatment 5. Late-breaking Clinical Trial Results from FARADISE, admIRE Study and Advent Trial at Heart Rhythm 2024 Highlight Pulsed Field Ablation Developments for Atrial Fibrillation Treatment 8.
Volta Medical has announced it has entered into a Joint Development Agreement with GE Healthcare to enhance arrhythmia procedures with artificial intelligence (AI)-driven electrophysiology technologies. Our mission to combat complex heart rhythm diseases relies on optimizing interoperability.
Pulmonary vein (PV) isolation is the cornerstone of radiofrequency (RF) ablation for atrial fibrillation (AF). PV reconnection is the most common cause of recurrent AF following an ablation procedure. Additionally, the relationship between impedance drop during ablation lesion delivery and PV ostial WT is not well understood.
Pulsed field ablation (PFA) has recently been introduced as a novel ablationtechnology for pulmonary vein isolation (PVI) in patients with atrial fibrillation (AF). High rates of acute PVI have been observed based on electrograms of the PFA device only.
No data have been reported on cooling characteristics and the impact of variant pulmonary vein (PV) anatomy on atrial fibrillation (AF) recurrences after POLARx cryoballoon (CB) ablation.
Cryoballoon (CB) ablation is the mainstay of single-shot pulmonary vein isolation (PVI). However, these two technologies have not been compared. A radiofrequency balloon (RFB) catheter has recently emerged as an alternative.
a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases announced that the Unites States Patent Office has granted Patent No: 12,036,371 titled “Method of Accessing the Left Atrium with a Multi-Directional Steerable Catheter,” with a patent term that will expire in 2035.
Non-thermal pulsed field ablation (PFA) is an novel technology to perform pulmonary vein isolation (PVI) for atrial fibrillation (AF). Different PFA systems are available, but no comparative data exist.
a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, announced the completion of the first five procedures in its first-in-human feasibility study with its novel CellFX nsPFA cardiac catheter.
Abstract Introduction Through systematic scientific rigor, the CLOSE guided workflow was developed and has been shown to improve pulmonary vein isolation durability. However, this technique was developed at a time when using power-controlled ablation catheters with conventional power ranges was the norm.
Pulmonary vein isolation (PVI) with cryoballoon (CB) ablationtechnology is widely used to treat drug-resistant atrial fibrillation (AF). During CB ablation, there is a possibility of forming an ice cap of con.
a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech , today announced European CE mark approval of the VARIPULSE Platform for the treatment of symptomatic drug refractory recurrent paroxysmal atrial fibrillation ( AF ) using pulsed field ablation (PFA). iii] The study reported a low fluoroscopy time of 7.8
The 1st generation HeartLight laser balloon (LB) ablation is highly effective in achieving pulmonary vein isolation (PVI), and the safety and 12-month efficacy are comparable with paroxysmal atrial fibrillation (PAF) ablationtechnologies.
Abstract Background The newly introduced nonthermal pulsed field ablation (PFA) is a promising technology to achieve fast pulmonary vein isolation (PVI) with high acute success rates and good safety features. Data comparing PFA to VHPSD-PVI is lacking. One clinically nonsignificant PV stenosis occurred in the VHPSD group.
Pulsed field ablation (PFA) has recently been introduced as a novel routine ablationtechnology for paroxysmal atrial fibrillation (AF). It is also used as off-label therapy for persistent AF.
One of the most significant recent advances in developing new technologies for the interventional treatment of atrial fibrillation (AF) has been the introduction of pulsed field ablation (PFA).1
We have employed digital twin technology to perform extra pulmonary vein (PV) ablation in patients with non-paroxysmal atrial fibrillation (AF). We reported that high dominant frequency (DF) site ablation improved rhythm outcomes, but high maximal slope of action potential restitution curve (Smax) site ablation did not.
Pulsed-field ablation (PFA) is novel ablative technology utilizing high-voltage, ultra-short electrical pulses to induce electroporation and cell apoptosis. The PFA dose needed to induce chronic lesion formation requires further assessment.
This study investigated myocardial injury and inflammation following pulmonary vein isolation using (1) Standard radiofrequency ablation, (2) very high-power short-duration (vHPSD)-70W, (3) vHPSD-90W, and (4) pulsed-field ablation (PFA). Results Baseline characteristics were well-balanced between groups (age 63.1 ± 10.3
Pulsed field ablation (PFA) is an emerging technology that applies high voltage electrical pulses to cardiac tissue selectively and induces cell death through predominately non-thermal irreversible electroporation.
Pulsed-field ablation (PFA) is becoming increasingly relevant in the field of electrophysiology. Besides single-shot PFA devices for pulmonary vein isolation (PVI), point-by-point PFA is also gaining importance due to many possible applications. Data on the use is sparse, especially for atrial tachycardia (AT).
ABSTRACT Introduction The extensive use of pulsed field ablation (PFA) in clinical settings has unveiled new evidence suggesting potential involvement in red blood cell structural impairment resulting in hemolysis and potential acute kidney injury (AKI).
Abstract Introduction Catheter ablation of atrial fibrillation (AF) has emerged as the most effective therapy. However, rare anatomical abnormalities such as situs inversus totalis, dextrocardia, or interrupted inferior vena cava can make ablation challenging.
Characteristics of acute insufficient lesions during vHPSD ablation were analyzed in the retrospective phase. Based on these data, an optimized approach combining both vHPSD ablation and AI-guided ablation was prospectively tested, resulting in an approximately 90% first-pass PVI rate. 0001) with shorter ablation time ( p =.04).
Abstract Introduction Despite advanced ablation strategies and major technological improvements, treatment of persistent atrial fibrillation (AF) remains challenging and the underlying pathophysiology is not fully understood. Randomized studies are necessary to evaluate long-term efficacy of dispersion-guided ablation using AI.
Left atrial (LA) low voltage area (LVA) burden correlates with AF recurrence risk post pulmonary vein isolation. Adjunctive ablation targeting LVAs, has been reported to improve outcomes. Omnipolar technology (OT) overcomes many limitations of BiV mapping, however there is little data on equivalent OT thresholds.
ABSTRACT Introduction Pulmonary vein isolation (PVI) using a cryoballoon is well-established for the treatment of paroxysmal atrial fibrillation (PAF). Compared to other available technologies, the usage of a stable, low-pressure cryoballoon (POLARx, Boston Scientific) has demonstrated lower nadir temperatures and longer thawing times.
By the 1960s, advances in technology and medical research led to the emergence of automated ECG interpretation (AEI), based on physician-developed rules of classification. By 1909 ECGs were being used to diagnose cases of arrhythmia; by 1910 to diagnose indicators of a heart attack.
PFA is the latest ablation modality approved by the Food and Drug Administration that can be used to restore a regular heartbeat. Given the relative novelty of pulsed field ablation, these are important safety outcomes.” Patients with AF can undergo a catheter procedure, called catheter ablation, to treat this abnormal heart rhythm.
Abstract Introduction Pulsed field ablation (PFA) is a new ablationtechnology for atrial fibrillation (AF). Data regarding early recurrences of atrial tachyarrhythmia (ERAT) after PFA-pulmonary vein isolation (PVI) are sparse. Methods Consecutive patients with symptomatic AF were enrolled to undergo PFA-PVI.
Cortex gives Boston Scientific a new mapping technology that detects AFib signs and triggers outside of the pulmonary veins, and can help EP teams develop ablation strategies for more complex AFib cases. for an undisclosed sum.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content